This spring, when the Supreme Court of the United States (SCOTUS) debated whether to limit access to a widely used abortion medication, a majority of justices seemed inclined to rule against the lawsuit by finding that the antiabortion doctors behind it had no legal basis to bring the case.
That was the position of the Biden administration, whose lawyer pressed the justices to get rid of the challenge to the Food and Drug Administration's (FDA) regulation of mifepristone, first approved by the agency more than 20 years ago. Solicitor General Elizabeth Prelogar said the anti-abortion doctors are not directly harmed by regulations that have made it possible to ship the drug to patients' homes and use them later in pregnancy. She urged the justices to "say so and put an end to this case."
But a Supreme Court ruling along those lines, which could come as soon as Thursday and must land by the end of the court term in late June or early July, is unlikely to end the legal fight over access to the drug that is used in more than 60 percent of all U.S. abortions.
Please select this link to read the complete article from The Washington Post.